Pasithea Therapeutics Corp. (KTTA) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.06
↓-86% vs avg
5yr avg: 0.45
30Y Low0.2·High0.8
ROE
↓
-72.8%
↑-97% vs avg
5yr avg: -37.0%
30Y Low-73%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KTTA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pasithea Therapeutics Corp. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $19M | $3M | $9M | $16M | $41M | — |
| Enterprise Value | $12M | $-3470071 | $-7172532 | $-16375048 | $-12241909 | — |
| P/E Ratio → | -0.07 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | 2703.81 | — |
| P/B Ratio | 0.06 | 0.23 | 0.39 | 0.38 | 0.79 | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KTTA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | -812.77 | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
KTTA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -72.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | -14.7% | — |
| Operating Margin | — | — | — | — | -29925.7% | — |
| Net Profit Margin | — | — | — | — | -14430.5% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -72.8% | -72.8% | -48.4% | -29.7% | -8.4% | -25.5% |
| ROA | -65.9% | -65.9% | -44.8% | -28.3% | -8.1% | -24.8% |
| ROIC | -142.4% | -142.4% | -140.5% | -225.6% | — | — |
| ROCE | -74.2% | -74.2% | -47.9% | -26.2% | -17.0% | -25.5% |
KTTA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $7M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.01 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.47 | -0.69 | -0.77 | -1.03 | -1.01 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -123421.28 | -8872.86 | — |
Net cash position: cash ($7M) exceeds total debt ($0)
KTTA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pasithea Therapeutics Corp.'s current ratio of 6.58x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 18.15x to 6.58x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 6.58 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Quick Ratio | 6.58 | 6.58 | 6.34 | 18.15 | 119.17 | 37.55 |
| Cash Ratio | 6.18 | 6.18 | 6.20 | 17.62 | 118.42 | 36.90 |
| Asset Turnover | — | — | — | — | 0.00 | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
KTTA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pasithea Therapeutics Corp. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 41.1% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 41.1% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $1M | $1M | $1M | $1M | $688918 |
Peer Comparison
Compare KTTA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KTTAYou | $19M | -0.1 | — | — | — | — | -72.8% | -142.4% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 CYBN | $304M | -13.7 | — | — | — | — | -42.8% | -115.8% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ALTO | $351M | 28.4 | 12.8 | 40.6 | 3.8% | 0.8% | 5.7% | 1.9% | 3.0 |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See KTTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KTTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KTTA vs CMPS
Side-by-side business, growth, and profitability comparison vs COMPASS Pathways plc.
Start ComparisonKTTA — Frequently Asked Questions
Quick answers to the most common questions about buying KTTA stock.
What is Pasithea Therapeutics Corp.'s P/E ratio?
Pasithea Therapeutics Corp.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Pasithea Therapeutics Corp.'s ROE?
Pasithea Therapeutics Corp.'s return on equity (ROE) is -72.8%. The historical average is -37.0%.
Is KTTA stock overvalued?
Based on historical data, Pasithea Therapeutics Corp. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.